Treatment News

/Treatment News

Latest Treatment News in Neuroendocrine Tumours

68Ga-DOTATATE PET scan in Ontario

68Ga-DOTATATE PET scan in Ontario Cancer Care Ontario has announced that as of April 1st, 2019, Ontario patients with neuroendocrine tumours (NETs) meeting eligibility criteria are able to have [...]

By | 2019-04-12T23:00:13+00:00 April 12th, 2019|Treatment News|Comments Off on 68Ga-DOTATATE PET scan in Ontario

Health Canada approves XERMELO™ (telotristat ethyl)

Health Canada approves XERMELO™ (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea(1) "XERMELOTM is a novel, orally administered, inhibitor of the enzyme tryptophan hydroxylase [...]

By | 2018-10-17T14:45:09+00:00 October 17th, 2018|Treatment News|Comments Off on Health Canada approves XERMELO™ (telotristat ethyl)

Public Listings for Caprelsa

Caprelsa (vandetanib) is indicated for the treatment of symptomatic or progressive Medullary thyroid cancer in adult patients with unresectable locally advanced or metastatic disease. Alberta Health Services has put the [...]

By | 2018-09-18T23:32:14+00:00 September 18th, 2018|Treatment News|Comments Off on Public Listings for Caprelsa

Patient Input – Treatment with Telotristat

TELOTRISTAT is an adjunct to somatostatin analogue therapy for the long-term treatment of carcinoid syndrome to improve symptom control in adult patients with metastatic neuroendocrine tumours.The company who makes telotristat [...]

By | 2018-09-03T18:47:17+00:00 September 3rd, 2018|Survey, Treatment News|Comments Off on Patient Input – Treatment with Telotristat

Health Canada approves Ipsen’s Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)

Somatuline Autogel is the first and only somatostatin analog (SSA) approved in Canada to treat enteropancreatic neuroendocrine tumours and carcinoid syndrome. Februaury 13th, 2018 - Health Canada announced the approval [...]

By | 2018-05-07T18:28:10+00:00 February 13th, 2018|Treatment News|Comments Off on Health Canada approves Ipsen’s Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)

Diagnostic Scan – Ga68

The Gallium 68 scan, used with functional PET imaging, is a nuclear medicine scan that relies on the over-expression of somatostatin receptors to visualize tumours. NETs typically express several somatostatin receptor subtypes in [...]

By | 2018-05-07T18:28:11+00:00 October 4th, 2017|Treatment News|Comments Off on Diagnostic Scan – Ga68

Somatuline (lanreotide) Access in Manitoba & Alberta

As we advised previously, in July of this year the Manitoba government issued a bulletin http://www.gov.mb.ca/health/mdbif/…/bulletins/bulletin93.pdf that indicated a change in the listing for Somatuline (from 1 to 3 and no access [...]

By | 2018-05-07T18:28:11+00:00 October 2nd, 2017|Treatment News|Comments Off on Somatuline (lanreotide) Access in Manitoba & Alberta

Caprelsa (vandetanib) for Medullary Thyroid NETs

Caprelsa is indicated for the treatment of symptomatic or progressive medullary thyroid cancer (MTC) in adult patients with unresectable locally advanced or metastatic disease.   An application for this drug was [...]

By | 2018-05-07T18:28:11+00:00 October 2nd, 2017|Treatment News|Comments Off on Caprelsa (vandetanib) for Medullary Thyroid NETs